MMP9 and neoplasm: ATO may reduce various tumor cell activities, inhibit cell attachment to peritoneal mesothelial cells, enhance the interaction between tumor cells, downregulate the expression level of matrix metalloproteinase (MMP)-2 and MMP-9, and upregulate the expression level of MMP inhibitor (TIMP) [19].